Krawczyk, J., Swan, D., Quinn, J., Mykytiv, V., Cahill, M. R., Glavey, S., Hayat, A., Nunez, Y. P., O'Shea, D., Abdullah, S., Dyszkiewicz, A., Bakshi, S., Cussen, K., Egan, K., Hennessy, M., Matczuk, D., Sheehan, L., Clayton-Lea, A., McLoughlin, O., Marron, J., Donachie, V., Nolan, M., Cregg, F., Helanova, S., Beristain, I., Kiely, M., O'Rourke, R., Gallagher, S., Nataraj, A., Ryan, A., O'Dwyer, M. (2025). Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population. Blood. https://doi.org/10.1182/blood-2025-4031